December 3, 2021 10:54 AM EST
R&D
FDA+

Pfiz­er, Am­gen and Janssen seek fur­ther clar­i­ty on FDA's new ben­e­fit-risk guid­ance

Zachary Brennan

Senior Editor

Three top bio­phar­ma com­pa­nies are seek­ing more de­tails from the FDA on how the agency con­ducts its ben­e­fit-risk as­sess­ments for new drugs and bi­o­log­ics. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: White House threat­ens ‘most fa­vored na­tion’ plan to low­er US drug prices, but many ques­tions re­main

Trump says he'll sign or­der on 'most fa­vored na­tion' drug price plans Mon­day

Ex­clu­sive: Patrick Hsu start­up launch­es, looks be­yond CRISPR for gene in­ser­tion tech­nol­o­gy

Lil­ly says fur­ther head-to-head tri­al da­ta back Zep­bound over No­vo’s We­govy

Vir’s hep B dis­ap­point­ment, Ipsen's new Iqir­vo da­ta, plus more from #EASL25

FDA clears in vi­vo blood stem cell edit­ing tri­al; Abeon­a's $155M PRV sale

A service from the Financial Times